Catch­ing up with Keytru­da, Re­gen­eron scores front­line NSCLC ap­proval for Lib­tayo/chemo com­bo

Re­gen­eron’s Lib­tayo has made it in­to the ex­clu­sive club of PD-(L) in­hibitors ap­proved, in com­bi­na­tion with chemother­a­py, as a front­line treat­ment for a broad swath of lung can­cer pa­tients.

Based on Phase III over­all sur­vival da­ta, the FDA grant­ed Lib­tayo an ap­proval for the first-line treat­ment of adult pa­tients with ad­vanced non-small cell lung can­cer with no EGFR, ALK or ROS1 aber­ra­tions.

“Lib­tayo is now ap­proved for ex­tend­ing the sur­vival of pa­tients with ad­vanced non-small cell lung can­cer as both a monother­a­py in high PD-L1 ex­pres­sors and in com­bi­na­tion with chemother­a­py ir­re­spec­tive of PD-L1 ex­pres­sion lev­els, achiev­ing a high bar that has on­ly been met by one oth­er PD-1 tar­get­ing agent,” said Is­rael Lowy, SVP, trans­la­tion­al and clin­i­cal sci­ences, on­col­o­gy at Re­gen­eron.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER